Home » Stocks » Theratechnologies

Theratechnologies Inc. (THTX)

Stock Price: $2.19 USD 0.01 (0.46%)
Updated Jul 14, 2020 1:32 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 168.66M
Revenue (ttm) 47.53M
Net Income (ttm) -9.40M
Shares Out 77.01M
EPS (ttm) n/a
PE Ratio n/a
Forward PE 56.50
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 14, 2020
Last Price $2.19
Previous Close $2.18
Change ($) 0.01
Change (%) 0.46%
Day's Open 2.30
Day's Range 2.16 - 2.30
Day's Volume 31,589
52-Week Range 1.68 - 2.75

More Stats

Market Cap 168.66M
Enterprise Value 182.27M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 77.01M
Float 76.02M
EPS (basic) n/a
EPS (diluted) n/a
FCF / Share -0.06
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.11M
Short Ratio 2.45
Short % of Float 1.46%
Beta 1.50
PE Ratio n/a
Forward PE 56.50
P/FCF Ratio n/a
PS Ratio 3.55
PB Ratio 7.34
Revenue 47.53M
Operating Income -6.40M
Net Income -9.40M
Free Cash Flow -3.46M
Net Cash -13.61M
Net Cash / Share -0.18
Gross Margin 66.48%
Operating Margin -13.47%
Profit Margin -19.80%
FCF Margin -7.29%
ROA -6.30%
ROE -57.72%
ROIC -9.10%
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$5.44*
(148.40% upside)
Low
2.00
Current: 2.19
High
11.00
Target: 5.44
*Average 12-month USD price target from 5 stock analysts.

Financial Performance

Financial numbers in millions CAD.

Financial Overview

Year20192018201720132012201120102009
Revenue63.2245.2237.077.5513.5714.9331.8717.47
Revenue Growth39.81%21.97%390.82%-44.33%-9.12%-53.16%82.44%-
Gross Profit42.0234.4030.413.848.515.7831.4017.47
Operating Income-8.51-3.563.94-4.48-14.85-18.776.66-16.75
Net Income-12.50-4.700.41-4.06-13.94-17.738.93-15.16
Shares Outstanding61.0161.0161.0161.0160.8760.87--
Earnings Per Share-0.16-0.060.01-0.07-0.23-0.290.15-0.25
Operating Cash Flow-3.390.092.69-7.74-15.63-27.222.905.66
Capital Expenditures-1.22-0.03-0.030.06-0.07-0.23-0.42-0.41
Free Cash Flow-4.610.072.66-7.68-15.70-27.452.495.25
Cash & Equivalents40.6348.6917.891.071.663.3128.5111.56
Total Debt58.7349.237.15-----
Net Cash / Debt-18.10-0.5510.741.071.663.3128.5111.56
Assets11811159.1824.8436.3352.8771.6569.15
Liabilities92.7276.1025.736.3213.6616.5319.0026.11
Book Value24.8335.0133.4518.5322.6736.3452.6643.05
Numbers in millions CAD, except per-share numbers.

Company Profile

Company Details

Full Name Theratechnologies Inc.
Country Canada
Employees 42
CEO Paul Lévesque

Stock Information

Ticker Symbol THTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: THTX

Description

Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. The company's pipeline products include F8 Formulation that could be used for the treatment of HIV-associated lipodystrophy; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was founded in 1993 and is headquartered in Montreal, Canada.